Imatinib 1a Pharma (Imatinib)

Imatinib is used to inhibit abnormal tyrosine‑kinase signaling in specific hematologic and solid‑tumor cancers.

• Chronic Myeloid Leukemia (CML): achieves durable cytogenetic and molecular responses in patients with BCR‑ABL positive disease.
• Gastrointestinal Stromal Tumor (GIST): reduces tumor progression by blocking c‑KIT and PDGFR signaling.
• Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): improves remission rates when combined with chemotherapy.

• Imatinib selectively inhibits the BCR‑ABL tyrosine kinase as well as c‑KIT and platelet‑derived growth factor receptors (PDGFR). By binding to the ATP‑binding site of these enzymes, it blocks downstream proliferative signaling pathways, leading to reduced malignant cell growth and induction of apoptosis in affected tissues.

Adverse reactions to Imatinib may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Fatigue: generalized tiredness.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Diarrhea: loose stools, sometimes watery.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Cardiotoxicity: left ventricular dysfunction or heart failure.
• Severe neutropenia: markedly reduced neutrophil count increasing infection risk.
• Hemorrhagic events: bleeding due to platelet dysfunction.

Patients and prescribers should consider several safety measures before and during therapy.

• Baseline assessment: obtain complete blood count, liver function tests, and renal function before initiating treatment.
• Monitoring: perform regular hematologic and biochemical monitoring to detect early toxicity.
• Drug interactions: review concomitant medications for potential CYP3A4 modulators.
• Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce plasma concentrations.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can increase exposure and toxicity.
• Antacids containing aluminum or magnesium: may decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Proton pump inhibitors: may modestly reduce bioavailability.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Vaccines: live attenuated vaccines should be avoided during treatment.